BrainStorm reports Q2 EPS (4c) vs. (13c) last year.

Cash, cash equivalents, and restricted cash amounted to approximately $3.65M, as of June 30. “We continue to make excellent progress in our preparations for the planned Phase 3b trial of NurOwn in ALS, with important recent developments on regulatory and operational fronts,” said Chaim Lebovits, President and CEO of BrainStorm. “We believe that the regulatory aspects of the program have been substantially derisked, having secured agreement with the FDA on a Special Protocol Assessment and also reached alignment on the CMC aspects. We have selected a leading Clinical Research Organization and are actively working to establish multiple trial sites. If successful, this trial has the potential to significantly improve the lives of ALS patients by providing a much-needed therapeutic option.”